FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL
--------------

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* $ \underline{Koppel\ Adam} $						2. Issuer Name and Ticker or Trading Symbol PTC THERAPEUTICS, INC. [ PTCT ]							ationship of R all applicabl Director		10% Owne			
(Last) (First) (Middle) C/O BROOKISDE CAPITAL MANAGEMENT, L JOHN HANCOCK TOWER, 200 CLARENDON S					3. Date 06/25		st Transact	tion (Month/Day/Year)					Officer (girbelow)	ve title	Other (speci below)		pecify	
(Street)  BOSTON MA 02116  (City) (State) (Zip)					4. If Ar	If Amendment, Date of Original Filed (Month/Day/Year)						6. Indiv	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 ar		A) or	5. Amount of Securities Beneficially Following Re		Owned (D) or In		. Nature of ndirect Beneficial Ownership		
								v	Amount	(A) or (D)	Price	Transaction( (Instr. 3 and				nstr. 4)		
Common Stock 0					06/25/2013		С			1,083,333	3 A	(1)	1,083,333				See Sootnote <sup>(2)</sup>	
Common Stock				06/25/2013						1,250,000	0 A	\$15	2,333,333				Gee Gootnote <sup>(3)</sup>	
			Table II -							osed of, o			ned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) Instr. 3, 4 and 5)		6. Date Exercis Expiration Dat (Month/Day/Ye		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number o derivative Securities Beneficially Owned Following	ive ties cially	10. Ownershi Form: Direct (D) or Indirect	Beneficial Ownership t (Instr. 4)	
	Security			Code	v	(A)	(D)	Date Exerci	isable	Expiration Date	Title	Amount or Number of Shares		Report	ed ction(s)	(I) (Instr. 4		
Series Four Senior Preferred Stock	(1)	03/07/2013		A		1,083,333		(1	1)	(1)	Common Stock	1,083,333	\$12	1,083	3,333	I	See Footnote <sup>(2)</sup>	
Series Four Senior	(1)	06/25/2013		С			1,083,333	(1)		(1)	Common Stock	1,083,333	\$0	(	0	I	See Footnote <sup>(2)</sup>	

## **Explanation of Responses:**

Stock

- 1. All outstanding shares of Series Four Senior Preferred Stock were automatically converted into Common Stock upon the closing of the Issuer's initial public offering, for no additional consideration.
- 2. Dr. Adam Koppel is a Managing Director of Brookside Capital Management, LLC ("BCM"). BCM is the sole general partner of Brookside Capital Investors, L.P. ("BCI"), which is the general partner of Brookside Capital Partners Fund, L.P. ("BCP Fund"). By virtue of these relationships, Dr. Koppel may be deemed to beneficially own the securities held by the BCP Fund. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
- 3. BCM is also the sole general partner of Brookside Capital Investors II, L.P. ("BCI II"). BCI II is the sole general partner of Brookside Capital Trading Fund, L.P. ("BCT Fund"). By virtue of these relationships, Dr. Koppel may be deemed to beneficially own the securities held by the BCT Fund. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

06/27/2013 /s/ Dr. Adam Koppel

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.